| Name | Title | Contact Details |
|---|
Quva is a national provider specializing in health-system pharmacy services, focusing on sterile injectable compounding and advanced data software platforms. The company operates FDA-registered 503B outsourcing facilities that manufacture ready-to-administer compounded sterile pharmaceuticals, serving thousands of hospitals across the United States. Quva adheres to stringent cGMP standards and utilizes automation and integrated technologies to ensure a reliable supply of high-quality medications. Quvas operations are divided into two main divisions. Quva Pharma delivers essential sterile compounded medications, addressing supply chain reliability and medication shortages. Quva BrightStream offers a data analytics platform that aggregates and analyzes healthcare data, providing actionable insights to optimize pharmacy operations. The company emphasizes patient safety, transparent customer service, and a commitment to innovation and quality, making it a trusted partner for health systems and hospital pharmacies.
Bellen Health Care System is a Green Bay, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Juno Therapeutics is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body`s immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling evidence of tumor shrinkage in clinical trials in refractory leukemia and lymphoma conducted to date. Juno`s long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from some of the world`s leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children`s Research Institute, and The National Cancer Institute. Juno Therapeutics has an exclusive license to the St. Jude Children`s Research Hospital patented technology for CD19 directed product candidates that use 4-1BB, which was developed by Dario Campana, Chihaya Imai, and St. Jude Children`s Research Hospital.
Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is a third generation autologous cellularized scaffold product that is indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the adult knee, with or without bone involvement. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing 1 additional cell product. Ixmyelocel-T is a multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). Developing autologous (patient`s own) cell therapies—with integrity Vericel uses rigorous scientific methods to develop novel therapies for the treatment of patients with autologous (patient`s own) cells. In addition, personal integrity, team work, collaboration, and innovative technology are the foundations of our work. We seek to practice transparency in our clinical trials and research, and in our relationships with each other, our patients, and the investors who support us.
Advanced Life Sciences is a Woodridge, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.